Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Delivery

Bicycle, Ionis sign oligonucleotide delivery pact

by Michael McCoy
July 18, 2021 | A version of this story appeared in Volume 99, Issue 26

 

Ionis Pharmaceuticals will pay Bicycle Therapeutics $45 million to license the firm’s bicyclic peptide technology. Bicycle is developing the synthetic short peptides as oncology treatments. But Ionis will use them to deliver oligonucleotide therapeutics to tissue, taking advantage of the high affinity for the transferrin receptor of some of Bicycle’s peptides. Bicycle will retain rights to use the peptides for all nonoligonucleotide delivery applications.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.